AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORCL
  4. [Form 4] Oracle Corp Insider Trading Activity

[Form 4] Oracle Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Bioceres Group Limited, Bioceres LLC and THEO I SCSp filed Amendment No. 15 to their Schedule 13D on Bioceres Crop Solutions (BIOX). The group executed open-market sales and enforced pledge agreements on 08 Aug 2025 to settle financial obligations, cutting record-owned shares from 18,561,323 to 12,421,323.

Post-transaction, the reporting persons beneficially own 15,497,402 ordinary shares, equal to 24.7 % of BIOX鈥檚 62.85 m shares outstanding. Voting power is largely shared: Bioceres Group holds 70,785 sole / 15,426,617 shared votes; Bioceres LLC 14,989,117 shared; THEO I SCSp 437,500 shared.

The filing states the disposals were undertaken solely to meet due liabilities and that the group presently has no plans or proposals regarding mergers, asset sales, board changes or other corporate actions under Item 4. No new contracts, litigation or additional agreements were disclosed.

Bioceres Group Limited, Bioceres LLC e THEO I SCSp hanno depositato l'Emendamento n. 15 al loro Schedule 13D su Bioceres Crop Solutions (BIOX). Il gruppo ha effettuato vendite sul mercato aperto e ha fatto valere accordi di pegno l'8 agosto 2025 per saldare obbligazioni finanziarie, riducendo le azioni detenute da 18.561.323 a 12.421.323.

Dopo la transazione, le persone segnalanti possiedono beneficiariamente 15.497.402 azioni ordinarie, pari al 24,7% delle 62,85 milioni di azioni in circolazione di BIOX. Il potere di voto 猫 in gran parte condiviso: Bioceres Group detiene 70.785 voti esclusivi e 15.426.617 condivisi; Bioceres LLC 14.989.117 condivisi; THEO I SCSp 437.500 condivisi.

Il deposito dichiara che le cessioni sono state effettuate esclusivamente per soddisfare passivit脿 dovute e che il gruppo attualmente non ha piani o proposte riguardanti fusioni, vendite di asset, cambiamenti nel consiglio o altre azioni societarie ai sensi del Punto 4. Non sono stati divulgati nuovi contratti, contenziosi o accordi aggiuntivi.

Bioceres Group Limited, Bioceres LLC y THEO I SCSp presentaron la Enmienda N潞 15 a su Schedule 13D sobre Bioceres Crop Solutions (BIOX). El grupo realiz贸 ventas en el mercado abierto y ejecut贸 acuerdos de prenda el 8 de agosto de 2025 para saldar obligaciones financieras, reduciendo las acciones en propiedad de 18.561.323 a 12.421.323.

Tras la transacci贸n, las personas informantes poseen beneficiariamente 15.497.402 acciones ordinarias, equivalentes al 24,7% de las 62,85 millones de acciones en circulaci贸n de BIOX. El poder de voto se comparte mayormente: Bioceres Group tiene 70.785 votos exclusivos y 15.426.617 compartidos; Bioceres LLC 14.989.117 compartidos; THEO I SCSp 437.500 compartidos.

El archivo indica que las disposiciones se realizaron 煤nicamente para cumplir con pasivos adeudados y que el grupo actualmente no tiene planes o propuestas respecto a fusiones, ventas de activos, cambios en la junta u otras acciones corporativas bajo el 脥tem 4. No se revelaron nuevos contratos, litigios ni acuerdos adicionales.

Bioceres Group Limited, Bioceres LLC 氚� THEO I SCSp電� Bioceres Crop Solutions (BIOX)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 15順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 攴鸽９鞚� 2025雲� 8鞗� 8鞚� 旮堨湹 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 瓿店皽 鞁滌灔鞐愳劀 毵る弰 氚� 雼措炒 瓿勳暯鞚� 鞁ろ枆頃橃棳 氤挫湢 欤检嫕鞚� 18,561,323欤检棎靹� 12,421,323欤茧 欷勳榾鞀惦媹雼�.

瓯半灅 頉� 氤搓碃鞛愲姅 15,497,402 氤错喌欤�毳� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 鞚措姅 BIOX鞚� 齑� 62.85氚彪 欤� 欷� 24.7%鞐� 頃措嫻頃╇媹雼�. 鞚橁舶甓岇潃 雽�攵�攵� 瓿奠湢霅橁碃 鞛堨溂氅�, Bioceres Group鞚� 雼弲 70,785響滌檧 瓿奠湢 15,426,617響�, Bioceres LLC電� 瓿奠湢 14,989,117響�, THEO I SCSp電� 瓿奠湢 437,500響滊ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟.

鞝滌稖 靹滊鞐愲姅 觳橂秳鞚� 鞓る歆� 毂勲 鞚错枆鞚� 鞙勴暣 鞚措（鞏挫鞙茧┌, 攴鸽９鞚� 順勳灛 頃╇硲, 鞛愳偘 毵り皝, 鞚挫偓須� 氤�瓴� 霕愲姅 旮绊儉 旮办梾頄夓渼鞐� 甏�頃� 瓿勴殟鞚措倶 鞝滌晥鞚� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靸堧鞖� 瓿勳暯, 靻岇啞 霕愲姅 於旉皜 頃╈潣電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Bioceres Group Limited, Bioceres LLC et THEO I SCSp ont d茅pos茅 l'Amendement n掳15 脿 leur Schedule 13D concernant Bioceres Crop Solutions (BIOX). Le groupe a r茅alis茅 des ventes sur le march茅 libre et fait valoir des accords de nantissement le 8 ao没t 2025 pour r茅gler des obligations financi猫res, r茅duisant les actions d茅tenues de 18 561 323 脿 12 421 323.

Apr猫s la transaction, les personnes d茅clarantes d茅tiennent b茅n茅ficiairement 15 497 402 actions ordinaires, soit 24,7 % des 62,85 millions d'actions en circulation de BIOX. Le pouvoir de vote est largement partag茅 : Bioceres Group d茅tient 70 785 voix exclusives et 15 426 617 voix partag茅es ; Bioceres LLC 14 989 117 voix partag茅es ; THEO I SCSp 437 500 voix partag茅es.

Le d茅p么t indique que les cessions ont 茅t茅 effectu茅es uniquement pour honorer des dettes dues et que le groupe n'a actuellement aucun plan ni proposition concernant des fusions, ventes d'actifs, changements au conseil d'administration ou autres actions d'entreprise selon l'Item 4. Aucun nouveau contrat, litige ou accord suppl茅mentaire n'a 茅t茅 divulgu茅.

Bioceres Group Limited, Bioceres LLC und THEO I SCSp haben 脛nderung Nr. 15 zu ihrem Schedule 13D bez眉glich Bioceres Crop Solutions (BIOX) eingereicht. Die Gruppe f眉hrte am 8. August 2025 Verk盲ufe am offenen Markt durch und setzte Pfandvereinbarungen durch, um finanzielle Verpflichtungen zu erf眉llen, wodurch die gehaltenen Aktien von 18.561.323 auf 12.421.323 reduziert wurden.

Nach der Transaktion besitzen die meldenden Personen wirtschaftlich 15.497.402 Stammaktien, was 24,7 % der 62,85 Mio. ausstehenden BIOX-Aktien entspricht. Die Stimmrechte sind gr枚脽tenteils geteilt: Bioceres Group h盲lt 70.785 alleinige und 15.426.617 gemeinsame Stimmen; Bioceres LLC 14.989.117 gemeinsame; THEO I SCSp 437.500 gemeinsame Stimmen.

Die Einreichung gibt an, dass die Ver盲u脽erungen ausschlie脽lich zur Erf眉llung f盲lliger Verbindlichkeiten erfolgten und dass die Gruppe derzeit keine Pl盲ne oder Vorschl盲ge bez眉glich Fusionen, Verm枚gensverk盲ufen, Vorstands盲nderungen oder anderen Unternehmensma脽nahmen gem盲脽 Punkt 4 hat. Es wurden keine neuen Vertr盲ge, Rechtsstreitigkeiten oder zus盲tzlichen Vereinbarungen offengelegt.

Positive
  • Reporting group retains a substantial 24.7 % stake, preserving significant influence over BIOX.
  • Filing confirms no current plans for mergers, asset sales or control changes, reducing near-term strategic uncertainty.
Negative
  • Ownership fell by roughly 3.1 m shares (鈮�5 % of outstanding) due to sales and pledge enforcement.
  • Divestiture undertaken to satisfy financial obligations may signal liquidity pressure at the parent entities.

Insights

TL;DR: Position cut by 3 m shares yet remains influential; neutral-to-slightly negative signal.

The sale reduces beneficial ownership from 29.5 % (estimated) to 24.7 %, a material 3.1 m-share decline. While the group still wields meaningful control, selling to cover obligations hints at cash-flow stress at the parent level rather than confidence in BIOX. Because control is largely maintained, operational influence over the issuer is unchanged, but reduced alignment may weigh on market perception. No activist intent tempers governance risk.

TL;DR: Stake cut, pledge enforcement suggests creditor influence; modest governance concern.

Enforcement of 2022 pledge agreements means creditors forced part of the divestiture. Such events can introduce external parties into the ownership structure and imply tightened financing terms for the reporting entities. However, the remaining 24.7 % block, combined with shareholder-agreement voting rights, still grants Bioceres substantial sway over board matters. Lack of further strategic plans limits immediate governance disruption.

Bioceres Group Limited, Bioceres LLC e THEO I SCSp hanno depositato l'Emendamento n. 15 al loro Schedule 13D su Bioceres Crop Solutions (BIOX). Il gruppo ha effettuato vendite sul mercato aperto e ha fatto valere accordi di pegno l'8 agosto 2025 per saldare obbligazioni finanziarie, riducendo le azioni detenute da 18.561.323 a 12.421.323.

Dopo la transazione, le persone segnalanti possiedono beneficiariamente 15.497.402 azioni ordinarie, pari al 24,7% delle 62,85 milioni di azioni in circolazione di BIOX. Il potere di voto 猫 in gran parte condiviso: Bioceres Group detiene 70.785 voti esclusivi e 15.426.617 condivisi; Bioceres LLC 14.989.117 condivisi; THEO I SCSp 437.500 condivisi.

Il deposito dichiara che le cessioni sono state effettuate esclusivamente per soddisfare passivit脿 dovute e che il gruppo attualmente non ha piani o proposte riguardanti fusioni, vendite di asset, cambiamenti nel consiglio o altre azioni societarie ai sensi del Punto 4. Non sono stati divulgati nuovi contratti, contenziosi o accordi aggiuntivi.

Bioceres Group Limited, Bioceres LLC y THEO I SCSp presentaron la Enmienda N潞 15 a su Schedule 13D sobre Bioceres Crop Solutions (BIOX). El grupo realiz贸 ventas en el mercado abierto y ejecut贸 acuerdos de prenda el 8 de agosto de 2025 para saldar obligaciones financieras, reduciendo las acciones en propiedad de 18.561.323 a 12.421.323.

Tras la transacci贸n, las personas informantes poseen beneficiariamente 15.497.402 acciones ordinarias, equivalentes al 24,7% de las 62,85 millones de acciones en circulaci贸n de BIOX. El poder de voto se comparte mayormente: Bioceres Group tiene 70.785 votos exclusivos y 15.426.617 compartidos; Bioceres LLC 14.989.117 compartidos; THEO I SCSp 437.500 compartidos.

El archivo indica que las disposiciones se realizaron 煤nicamente para cumplir con pasivos adeudados y que el grupo actualmente no tiene planes o propuestas respecto a fusiones, ventas de activos, cambios en la junta u otras acciones corporativas bajo el 脥tem 4. No se revelaron nuevos contratos, litigios ni acuerdos adicionales.

Bioceres Group Limited, Bioceres LLC 氚� THEO I SCSp電� Bioceres Crop Solutions (BIOX)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 15順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 攴鸽９鞚� 2025雲� 8鞗� 8鞚� 旮堨湹 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 瓿店皽 鞁滌灔鞐愳劀 毵る弰 氚� 雼措炒 瓿勳暯鞚� 鞁ろ枆頃橃棳 氤挫湢 欤检嫕鞚� 18,561,323欤检棎靹� 12,421,323欤茧 欷勳榾鞀惦媹雼�.

瓯半灅 頉� 氤搓碃鞛愲姅 15,497,402 氤错喌欤�毳� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 鞚措姅 BIOX鞚� 齑� 62.85氚彪 欤� 欷� 24.7%鞐� 頃措嫻頃╇媹雼�. 鞚橁舶甓岇潃 雽�攵�攵� 瓿奠湢霅橁碃 鞛堨溂氅�, Bioceres Group鞚� 雼弲 70,785響滌檧 瓿奠湢 15,426,617響�, Bioceres LLC電� 瓿奠湢 14,989,117響�, THEO I SCSp電� 瓿奠湢 437,500響滊ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟.

鞝滌稖 靹滊鞐愲姅 觳橂秳鞚� 鞓る歆� 毂勲 鞚错枆鞚� 鞙勴暣 鞚措（鞏挫鞙茧┌, 攴鸽９鞚� 順勳灛 頃╇硲, 鞛愳偘 毵り皝, 鞚挫偓須� 氤�瓴� 霕愲姅 旮绊儉 旮办梾頄夓渼鞐� 甏�頃� 瓿勴殟鞚措倶 鞝滌晥鞚� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靸堧鞖� 瓿勳暯, 靻岇啞 霕愲姅 於旉皜 頃╈潣電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Bioceres Group Limited, Bioceres LLC et THEO I SCSp ont d茅pos茅 l'Amendement n掳15 脿 leur Schedule 13D concernant Bioceres Crop Solutions (BIOX). Le groupe a r茅alis茅 des ventes sur le march茅 libre et fait valoir des accords de nantissement le 8 ao没t 2025 pour r茅gler des obligations financi猫res, r茅duisant les actions d茅tenues de 18 561 323 脿 12 421 323.

Apr猫s la transaction, les personnes d茅clarantes d茅tiennent b茅n茅ficiairement 15 497 402 actions ordinaires, soit 24,7 % des 62,85 millions d'actions en circulation de BIOX. Le pouvoir de vote est largement partag茅 : Bioceres Group d茅tient 70 785 voix exclusives et 15 426 617 voix partag茅es ; Bioceres LLC 14 989 117 voix partag茅es ; THEO I SCSp 437 500 voix partag茅es.

Le d茅p么t indique que les cessions ont 茅t茅 effectu茅es uniquement pour honorer des dettes dues et que le groupe n'a actuellement aucun plan ni proposition concernant des fusions, ventes d'actifs, changements au conseil d'administration ou autres actions d'entreprise selon l'Item 4. Aucun nouveau contrat, litige ou accord suppl茅mentaire n'a 茅t茅 divulgu茅.

Bioceres Group Limited, Bioceres LLC und THEO I SCSp haben 脛nderung Nr. 15 zu ihrem Schedule 13D bez眉glich Bioceres Crop Solutions (BIOX) eingereicht. Die Gruppe f眉hrte am 8. August 2025 Verk盲ufe am offenen Markt durch und setzte Pfandvereinbarungen durch, um finanzielle Verpflichtungen zu erf眉llen, wodurch die gehaltenen Aktien von 18.561.323 auf 12.421.323 reduziert wurden.

Nach der Transaktion besitzen die meldenden Personen wirtschaftlich 15.497.402 Stammaktien, was 24,7 % der 62,85 Mio. ausstehenden BIOX-Aktien entspricht. Die Stimmrechte sind gr枚脽tenteils geteilt: Bioceres Group h盲lt 70.785 alleinige und 15.426.617 gemeinsame Stimmen; Bioceres LLC 14.989.117 gemeinsame; THEO I SCSp 437.500 gemeinsame Stimmen.

Die Einreichung gibt an, dass die Ver盲u脽erungen ausschlie脽lich zur Erf眉llung f盲lliger Verbindlichkeiten erfolgten und dass die Gruppe derzeit keine Pl盲ne oder Vorschl盲ge bez眉glich Fusionen, Verm枚gensverk盲ufen, Vorstands盲nderungen oder anderen Unternehmensma脽nahmen gem盲脽 Punkt 4 hat. Es wurden keine neuen Vertr盲ge, Rechtsstreitigkeiten oder zus盲tzlichen Vereinbarungen offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Magouyrk Clayton M.
(Last) (First) (Middle)
C/O DELPHI ASSET MGMT CORPORATION
200 S. VIRGINIA ST., SUITE 625
(Street)
RENO NV 89501
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ORACLE CORP [ ORCL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, OCI
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/04/2025 M 62,500 A $0 123,222 D
Common Stock 08/04/2025 F(1) 23,981 D $244.42 99,241 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 08/03/2021 J(3) 62,500(3) (4) (4) Common Stock 62,500 $0 62,500 D
Restricted Stock Unit (2) 09/20/2022 J(3) 176,186(3) (5) (5) Common Stock 176,186 $0 176,186 D
Restricted Stock Unit (2) 09/15/2023 J(3) 184,357(3) (6) (6) Common Stock 184,357 $0 184,357 D
Restricted Stock Unit (2) 09/19/2024 J(3) 167,075(3) (7) (7) Common Stock 167,075 $0 167,075 D
Restricted Stock Unit (2) 08/04/2025 M 62,500 (4) (4) Common Stock 62,500 $0 0 D
Explanation of Responses:
1. Shares withheld for payment of tax liability upon vesting of restricted stock units.
2. Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock.
3. Represents unvested restricted stock units ("RSUs") awarded prior to the Reporting Person becoming a Section 16 officer on June 2, 2025, which were inadvertently omitted from the Reporting Person's Form 3 filed with the Commission on June 12, 2025.
4. Includes 62,500 unvested RSUs from a previous grant of 250,000 RSUs granted on August 3, 2021; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.
5. Includes 176,186 unvested RSUs from a previous grant of 352,372 RSUs granted on September 20, 2022; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.
6. Includes 184,357 unvested RSUs from a previous grant of 245,809 RSUs granted on September 15, 2023; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.
7. Includes 167,075 unvested RSUs from a previous grant of 167,075 RSUs granted on September 19, 2024; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.
/s/ Aimee Weast by Aimee Weast, Attorney in Fact for Clayton M. Magouyrk (POA filed 6/12/2025) 08/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many BIOX shares does Bioceres Group now own?

The reporting persons beneficially own 15,497,402 shares, or 24.7 % of BIOX鈥檚 outstanding stock.

Why did Bioceres Group sell BIOX shares in August 2025?

Shares were sold and pledged shares enforced to fund the payment of financial obligations owed by the reporting entities.

How much did Bioceres Group鈥檚 stake decrease?

Record holdings dropped from 18,561,323 to 12,421,323 shares, a reduction of about 3.1 million shares.

Does Bioceres plan any corporate actions after this filing?

The filing states the group has no current plans or proposals related to mergers, asset sales, board changes or other Item 4 matters.

What is the voting power distribution among the Bioceres entities?

Bioceres Group: 70,785 sole / 15,426,617 shared; Bioceres LLC: 14,989,117 shared; THEO I SCSp: 437,500 shared voting rights.
Stock ORCL logo
Oracle Corp

NYSE:ORCL

ORCL Rankings

#13 Ranked by Market Cap
#1889 Ranked by Dividends

ORCL Latest News

Aug 7, 2025
Oracle Helps Customers Achieve Extreme Availability and Performance for Mission-Critical and Agentic AI Applications
Aug 6, 2025
Celent Recognizes Oracle for Excellence in Digital Banking Platforms
Jul 31, 2025
J.P. Morgan Payments Launches Cutting-Edge Supply Chain Finance Solution with Oracle
Jul 31, 2025
University Maternity Hospital Limerick Improves Care with Oracle Health
Jul 30, 2025
Oracle Supports White House's Vision for Healthcare Data Interoperability

ORCL Latest SEC Filings

Aug 7, 2025
[Form 4] Oracle Corp Insider Trading Activity
Aug 6, 2025
[Form 4] Oracle Corp Insider Trading Activity
Aug 6, 2025
[Form 4] Oracle Corp Insider Trading Activity
Aug 5, 2025
[144] Oracle Corp SEC Filing
Jul 28, 2025
[Form 4] Oracle Corp Insider Trading Activity

ORCL Stock Data

718.13B
1.64B
41.55%
44.82%
0.74%
Software - Infrastructure
Services-prepackaged Software
United States
AUSTIN